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Abstract: Despite the major progress made in the field of cancer biology, cancer is still one of the
leading causes of mortality, and prostate cancer (PCa) is one of the most encountered malignancies
among men. The effective management of this disease requires developing better anticancer agents
with greater efficacy and fewer side effects. Nature is a large source for the development of
chemotherapeutic agents, with more than 50% of current anticancer drugs being of natural origin.
Isothiocyanates (ITCs) are degradation products from glucosinolates that are present in members
of the family Brassicaceae. Although they are known for a variety of therapeutic effects, including
antioxidant, immunostimulatory, anti-inflammatory, antiviral and antibacterial properties, nowadays,
cell line and animal studies have additionally indicated the chemopreventive action without causing
toxic side effects of ITCs. In this way, they can induce cell cycle arrest, activate apoptosis pathways,
increase the sensitivity of resistant PCa to available chemodrugs, modulate epigenetic changes
and downregulate activated signaling pathways, resulting in the inhibition of cell proliferation,
progression and invasion-metastasis. The present review summarizes the chemopreventive role of
ITCs with a particular emphasis on specific molecular targets and epigenetic alterations in in vitro
and in vivo cancer animal models.
Keywords: angiogenesis; apoptosis; carcinogenesis; cell cycle; chemoprevention; epigenetics;
isothiocyanates; metastasis; prostate cancer; therapy resistance
1. Introduction
Over the past several decades, research on the action of plant bioactive constituents has been
focused predominantly on their benefits for human health. Today we can begin to explain why
consuming a diet rich in vegetables and fruits may lead to a reduced incidence of certain diseases,
such as cancer [1,2]. Plant secondary products have complementary and overlapping actions,
including the modulation of detoxification enzymes and the stimulation of the immune system,
the reduction of inflammation, the modulation of steroid metabolism, antibacterial and antiviral effects
and antioxidant effects.
One group of vegetables that has drawn a great deal of attention are the vegetables from the
family Brassicaceae (Cruciferae). The family Brassicaceae is a large group, having about 3000 species
in 350 genera, including several types of edible plants, which are sometimes referred to as ‘the
cabbage family’. The most well-known species within the Brassicaceae are edible vegetables such as
Brassica oleracea (broccoli, cabbage, cauliflower, etc.); B. rapa (turnip); B. napus (canola, leaf rape); B. nigra
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(black mustard); Sinapis alba (white mustard); Raphanus sativus (radish); Eruca sativa (salad rocket) and
Diplotaxis tenuifolia (perennial wall-rocket).
The benefits for human health associated to consumption of cruciferous plants could be
explained, in part, by to their rich composition in secondary metabolites (i.e., meaning that they
are not essential for plant growth), frequently called phytochemicals. Glucosinolates are the main
class of secondary metabolites that can be found in cruciferous crops. All glucosinolates have
a common core structure that consists of a β-thioglucoside N-hydroxysulfate with a side chain R
and a sulphur-linked β-D glucopyranoside moiety that derives from different types of amino acid
precursors. Glucosinolates can be grouped into three chemical classes: aliphatic, indole and aromatic,
according to whether their amino acid precursor is methionine, tryptophan or an aromatic amino
acid (tyrosine or phenylalanine), respectively. There is a substantial amount of data compiled on the
occurrence of glucosinolates in representative Brassica species [3–5]; to date, more than 120 individual
glucosinolates have been isolated from species of the family Brassicaceae and the allied families [6].
Glucosinolate concentration varies according to the species and cultivar, tissue type, physiological
age, plant health, environmental factors, insect attack and microorganism intrusion [3,4,7]. Upon cell
damage, glucosinolates undergo hydrolysis by myrosinase to yield glucose, sulfate and aglucones
that can undergo fragmentation and/or molecular rearrangement. Therefore, this process will yield
isothiocyanates (ITCs), thiocyanates, oxazolindine-2-thione and nitriles, depending on the specific
glucosinolate substrate, myrosinase isozyme, reaction pH and the presence of certain ions and the
activity of specific protein factors, such as the epithiospecifier protein (ESP) [6]. Notably, nearly all of
the protective activities of glucosinolates, among them that one against cancer, can be attributed to
their hydrolytic products, of which the ITCs are prominent examples [7–9]. For this reason there is
an increase in their value as therapeutic compounds to be used in medicine and their value as food
supplements for human diet [10].
2. Biological Activity of Glucosinolates and ITCs: Their Role in Cancer Prevention
The first evidence of the benefits of glucosinolate degradation products for human health comes
from investigations in the 1960s and 1970s, which used rodent models of chemical carcinogenesis [11].
Subsequently, this has been corroborated with models of genetic predisposition [12] and with
xenografts [13]. Likewise, an extensive review of epidemiological studies published prior to 1996
reported that the majority (67%) of case-control studies found an inverse association between some
type of cruciferous vegetable intake and cancer risk [14]. By way of example, Graham et al. [15]
reported that the risk of cancer is increased among individuals with low consumption of cabbage,
Brussels sprouts, and broccoli, and decreased among those with high consumption of these vegetables,
and pointed out that these findings are consistent with the decreased number of tumors in animals
challenged with carcinogens and fed compounds found in the same vegetables. Nowadays, it is known
that this protection is not organ-specific and it has been seen in the lung, esophagus, stomach, colon,
breast, bladder, pancreas, and prostate [16]. Likewise, this protective effect is attributed to subtoxic
concentrations of glucosinolate degradation products. Kirsh et al. [17] have observed that 3–5 servings
of broccoli or cauliflower per week could be cancer-preventive, however the therapeutical effective
concentration has not been determined in clinical studies so far.
During the last two decades, ITCs have gained attention as they are responsible for the cancer
chemopreventative properties attributed to cruciferous crops [18]. Thus, the anticarcinogenic effects
of phenethyl isothiocyanate (PEITC) are being the object of study of several clinical trials. On the
one hand, efforts are underway to determine its effectiveness in preventing lung cancer in smokers
(clinicaltrials.gov Identifier: NCT00005883) as well as in depleting mutant p53 within the oral cells
(clinicaltrials.gov Identifier: NCT01790204). On the other hand, Ravasco (clinicaltrials.gov Identifier:
NCT02468882) suspects that this ITC could modulate breast cancer progression and recurrence.
Attempts to understand the mechanisms of action of ITCs began in parallel with studies
demonstrating their protective effects in animal models of carcinogenesis. It is now widely recognized
that these mechanisms are multiple, so carcinogenesis could be inhibited both in an early and a late state.
These mechanisms include at least the following: alterations of carcinogen metabolism due to changes
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in the activities of drug-metabolizing enzymes; induction of cell cycle arrest and apoptosis; inhibition
of angiogenesis and metastasis; changes in histone acetylation status; and oxidant activities [19].
The antioxidant and pro-oxidant activity of ITCs, both in vivo and in vitro, has been reviewed
recently [19,20]. Although the oxidative damage induced by bioactive molecules derived from
cruciferous vegetables is one of the most common and well-known cytotoxicity mechanisms by
which they can kill cancer cells or at least retard the progression of this disease [19], the action of
these compounds over the other mechanisms previously mentioned is gaining more interest. Thus, we
will discuss the cancer chemopreventive role of glucosinolate degradation products in the following
sections, with a particular emphasis on specific molecular targets and epigenetic alterations in in vitro
and in vivo cancer animal models. In particular, we have mainly summarized the effects of PEITC,
sulforaphane (SFN), benzyl isothiocyanate (BITC) and allyl isothiocyanate (AITC) in prostate cancer
(PCa) among the different compounds derived from the hydrolysis of glucosinolates (Table 1).
Table 1. Glucosinolates related to cancer prevention, single bioactive components after their
hydrolysis classified into isothiocyanates, nitrile and indole compounds, and crucifer crops where these
compounds are abundant. In this review, compounds highlighted in bold will be dealt with in detail.
Hydrolysis Products
Glucosinolate Isothiocyanates (ITCs) Nitriles Indoles Crops or Species
Aliphatic
Glucoraphanin Sulforaphane (SFN) Sulforaphanenitrile Broccoli
Sinigrin Allyl isothiocyanate(AITC) Allyl nitrile
Kale, cabbage, Brussels sprouts,
cauliflower
Glucoiberin Iberin Kale, cabbage, cauliflower
Glucoerucin Erucin Cabbage, broccoli
Indolic
Glucobrassicin Indole-3-carbinol (I3C)




Water cress (Nasturtium officinalis),
white mustard (Sinapis alba), turnips
Glucotropaeolin Benzyl isothiocyanate(BITC)
Indian cress or garden nasturtium or
(Tropaeolum majus)
3. Role of ITC in Cancer Epigenetics
The importance of epigenetics on cancer initiation and development is a growing area of interest.
Different epigenetic changes, like aberrant DNA methylation, histone modifications, and microRNA
profiles, can induce altered gene expression and functional changes, such as tumor suppressor genes
silencing and/or activation of oncogenes [21], developing an important role in carcinogenesis [22–27].
DNA hypomethylation can facilitate genome instability and thus an enhanced expression of oncogenes,
whereas DNA hypermethylation can silence tumor suppressor genes, transcription factors, and genes
involved in the regulation of cell cycle and apoptosis [27]. DNA methyltransferases (DNAMTs) are
involved in DNA methylation patterns [28] and are overexpressed in many cancers, such as PCa [29],
lung cancer [30], leukemia [31], pancreatic cancer [32] or gastric cancer [33]. Histone molecules
contribute to genome stability and gene transcription [34], and some transcriptional modifications
(acetylation, deacetylation, methylation, phosphorylation and ubiquitination) can alter them [35] with
consequences on cancer development [24,25,36,37]. Other epigenetic events have been described, the
so-called “cancer progenitor cells” (CPCs), probably involved in the development of the metastatic
properties of tumors [38]. These cells should develop from a population of normal human stem cells
as a consequence of a multifactorial process including environmental, genetic and mainly epigenetic
changes [38,39].
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Since epigenetic deregulation appears at the startup and the development of cancer and it is
potentially reversible, many authors have proposed epigenetic intervention strategies for cancer
prevention and treatment [22]. Moreover, epigenetic biomarkers could be useful to diagnose cancer, as
well as to establish a prognosis of the disease. The development of epigenetic drugs (“epi-drugs”) as
well as the design of epigenetic diets against cancer may have a potential in the near future [40,41].
As previously described, cruciferous vegetables have demonstrated properties against cancer [42]
that could be attributed to ITC compounds found in these plants, at least in part. ITCs may be
regulators of DNAMTs, miRNAs, and inhibitors of histone deacetylases (HDACs) [42], affecting the
uncontrolled cellular proliferation and the viability of various types of cancer cells like breast [43,44],
leukemic [45], pancreatic [46], colon [47] or skin [48–50].
Among the cancers cited above, the concurrence of various aspects explains the interest in PCa and
the need for new therapeutic strategies to treat it. Essentially, these aspects include that it represents
one of the most common cancers in men, which is expected to increase with population aging, and that
it can develop resistance to conventional therapy [androgen deprivation therapy (ADT) resistance]
over the course of the disease that is associated with poor prognosis and metastasis [51]. Studies
performed with PCa cells [27,51] provide evidence that ITCs may act as epigenetic modulators, thus
having consequences on the initiation and progression of carcinogenesis [27,51,52]. Their effects can
help restore cells to a more normal state [51].
SFN has been found to modulate some epigenetic mechanisms like DNAMT expression and
DNA methylation in both normal and cancerous (androgen-dependent and androgen-independent)
prostate cells [27,43,53,54]. These effects of SFN on DNA methylation can lead to the re-expression of
some tumor suppressor genes that got silenced in cancer cells. Likewise, SFN can also inhibit HDAC
activities upregulated in cancer [55–58]. In particular, SFN can inactivate the HDAC6, influencing the
acetylation state of HSP90 (a key androgen receptor (AR) chaperone) attenuating AR signaling [58],
and then androgen-dependent PCa cell growth.
The pathogenesis of PCa is dependent upon signaling through the activation by the androgen
ligands testosterone or dihydrotestosterone of the steroid nuclear hormone AR, inducing or repressing
gene expression through binding to chromatin at cis androgen response elements resulting in
an increase of cell growth [59]. Since Huggins et al. evidenced in 1941 [60] the benefit of androgen
deprivation in advanced metastatic PCa, androgen deprivation therapy (ADT) became a standard
of care that continues to this day for patients with cancer recurrence after a definitive primary
therapy, locally advanced disease or metastatic PCa. Nevertheless, although most patients initially
respond favourably to hormonal therapy, the disease progresses to a more severe stage termed
castration-resistant disease (CRPC) [59].
PEITC is another ITC with effects on PCa involving different epigenetic mechanisms. These
include, like other HDAC inhibitors [61,62], the downregulation of AR expression at transcriptional
and posttranslational levels [63]. This compound, as well as other ITCs and some metabolites, can
decrease the levels and activities of cdk/cyclins and increase the activity of the transcriptional factor
Sp1 [64,65], which is a regulator of AR expression in PCa [51,66]. PEITC can also restore the expression
of the detoxifying phase II enzyme π-class glutathione-S-transferase (GSTP1), which is silenced in
the vast majority of prostate tumor cells [51,67,68], via CpG island demethylation [69]. Studies using
TRAMP mice also showed that PEITC treatment can inhibit the CGI hypermethylation that occurs at
the early stage of prostate carcinogenesis [51].
4. In Vitro Studies
At the molecular level, the PCa cells can acquire mutations or epigenetic modifications that trigger
the malignant phenotype with the capacity of uncontrolled growth, survival, and invasion-metastasis.
As a result, the activation of receptors and growth factors, signaling proteins, kinases, transcription
factors and coregulators, and multiple proteases required for tumor progression can occur. Conceivably,
PCa cells could be interrupted along these different key points, which have been established as
a potential target for PCa therapy [70].
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This section, focusing on in vitro studies, highlights the possible molecular mechanisms of action
of ITCs against specific targets in three PCa cells (DU 145, PC3, and LNCaP cells). This triad of cells
represents the gold standard of PCa cell lines in culture [71]. These cells differ fundamentally in terms
of p53 and Bax status [72,73] and androgen sensitivity [72], where DU 145 is p53 mutant and Bax
negative but PC3 and LNCaP are p53 null and p53 wild-type, respectively. Furthermore, LNCaP are
androgen-dependent cells and DU 145 and PC3 are androgen-independent cells, being PC3 more
aggressive cancer cells.
Some evidence suggests that ITCs not only suppress PCa development during the “post-initiation”
phase of cancer via the induction of cell cycle arrest and apoptosis (see Sections 4.1 and 4.2 below) but
also the invasion-metastasis (see Section 4.3) and ADT resistance (see Section 4.4) in a dynamic and
cell type-specific manner. However, the effect of the ITCs should not be extrapolated between them.
4.1. Effects on Cell Cycle Proteins: Cell Cycle Arrest
Mitosis regulators can push cells forward into mitosis or hold them in G2-arrest. Both WEE1
and its complementary counterpart, cell division cycle 25C (Cdc25C), represent the main switch for
mitosis by means of double-activating feedback loops. Thus, in order to facilitate the progression of
mitosis, activated cyclin-dependent kinase 1 (Cdk1) activates and inactivates its activators (Cdc25C
and MastL) and inactivators (WEE1 and MYT1 (membrane associated tyrosine/threonine 1) kinases),
respectively [74–76]. There are three parallel Cdk1-inactivating pathways: CHK1/WEE1/Cdc25C/
Cdk1, MYT1/Cdk1, and PP2A/WEE1/Cdc25C [74] (Figure 1).
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CDK1–cyclin B triggers entry into mitosis and a dashed line represents Cdk1-inactivating pathways
(CHK1/WEE1/Cdc25C/Cdk1, MYT1/Cdk1, and PP2A/WEE1/Cdc25C). Abbreviations: Cdk1,
cyclin-dependent kinase 1; CHK1, checkpoint kinase 1; MYT1, membrane associated tyrosine/threonine
1 kinases; PP2A, protein phosphatase 2.
The Cdc25 family (Cdc25A, Cdc25B and Cdc25C) is upregulated in PCa and its expression level
is positively associated with the Gleason score and disease metastasis [77–79]. Moreover, it is an AR
coregulator suppressing the AR transcriptional activity [77,79]. In contrast, WEE1 can be considered
a tumor suppressor, which, being lost in normal prostate epithelial cells, increases the susceptibility to
genetic aberrations and carcinogenic transformation [76].
Besides WEE1, there are other tumor suppressors such as p21 or p53 that fail to restrict cell
cycling in PCa. The p21 protein (known also as WAF1, CAP20, CIP1, and SDI1), a member of the
CIP/KIP family of Cdk inhibitor , is a tumor suppressor as w ll as a cell cycle inhibitor protein [80].
Additionally, the expression of p21 appears associated with the progression of androgen-independent
prostate cancer (AIPC) [81]. The p53 is a downstream target of Chk2 kinase governing the G2/M
transition by transcriptional regulation of Cdk inhibitor p21. Additionally, the p53 status of PCa
cells may determine the response to radiation therapy; including the number and the proportion of
genes upregulated or downregulated after irradiation [72,80]. Furthermore, p53 is considered a tumor
suppressor that is a key target in cancer therapy [82].
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AITC (20 µM) induces G2/M phase arrest both in androgen-dependent (LNCaP) and -independent
(PC3) PCa cells, but not in the normal prostate epithelial cell line (PrEC). This effect, in both PCa cell
lines, is attributed to a decreased expression of the proteins involved in G2/M progression: Cdk1,
Cdc25B and Cdc25C, participating also cyclin B1 protein in LNCaP cells [83].
There are different mechanisms of action for PEITC that could contribute to G2/M phase arrest
in PCa cells [66,84–87]: (i) downregulation of Cdk1 and cyclin B1 protein expression in LNCaP
cells. This effect is extensible to the PEITC metabolite, PEITC-NAC (N-acetylcysteine conjugate of
phenethyl isothiocyanate), which is produced as a result of absorption and metabolism in humans
by conjugation of glutathione followed by conversion via the mercapturic acid pathway to a NAC
conjugate [85]; (ii) upregulation of p53 and WEE1 expression and downregulation of Cdc25C protein
in DU 145 cells [86]; (iii) downregulation of c-Myc in PC3, relieving the suppressive effect on the
promoter p21 [66]; (iv) proteasome-mediated degradation of Cdk1 and Cdc25C correlated with the
increase of the accumulation of Tyr15 phosphorylated (inactive) Cdk1 in PC3 cells [84].
It seems that SFN arrests cell cycle because it induces: (i) a decrease in protein levels of cyclin
D1, cyclin E, Cdk4, and Cdk6 in LNCaP cells [88]; (ii) checkpoint kinase 2-mediated phosphorylation
of Cdc25C, inducing its sequestration in the cytosol in DU 145 cells [89]; (iii) c-Jun N-terminal kinase
activation in DU 145 cells [89,90]; (iv) induction of p21 in PC3 and LNCaP cells regardless of p53
dependent and independent contexts [75]. SFN (20 µM) induces p53 [55] and p21 in LNCaP cancer
cells [55,88], but the induction of p21 seems to be independent of p53, since it occurs in the absence of
the induction of p53 and Ser15 phosphorylation, and it is probably associated with the inhibition of
HDAC activity. In accordance with this aspect, SFN induces cell cycle arrest which is not substantially
modified by the knockdown of p53. Also, SFN induces S phase arrest in LNCaP cells. It seems due to
induction of cyclin B1 and down-regulation of Cdk1 and Cdc25C [88]. BITC induces G2/M phase arrest
in DU 154 cells by increasing WEE1 levels and decreasing cyclin B1 and Cdc25C proteins levels [91].
The effects of ITCs on mitosis are not extrapolatable between them. Subtle differences in the
chemical structure may be responsible for the differences in their effects [92]. It is suggested that the
effect of ITCs on cell cycle is structure-dependent. Thus, PITC, a structural analogue of PEITC, losing
the –CH(2) spacers that link the aromatic ring to the –N=C=S group, has no effect on cell cycle arrest or
apoptosis, while PEITC has an effect on these parameters in PC3 [84] or DU 145 cells [93]. Likewise,
the characteristics of the PCa cells could also influence the effect of a particular ITC. It seems that,
besides an overall effect of SFN on the expression of cell cycle related genes, there is a specific effect
depending on the prostatic cell line and perhaps the state of cancer progression [94]. Table 2 and
Figure 2 summarize the possible effect of ITCs on mitosis regulators, their substrates or both, according
to the type of ITCs and prostate cell line.
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Figure 2. Effects of ITCs in vitro on cell cycle regulation by Cdk/cyclin holoenzymes and CKIs.
Abbreviations: Ò, enhanced expression r protein levels; Ó, r duced expression or protein levels; AITC,
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SFN-NAC, N-acetylcysteine conjugate of sulforaphane.
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Table 2. Cell cycle arrest induced by ITCs in vitro.
ITC Cells Factor RegulatoryPartner(s) Substrate Effect Ref.
AITC LNCaP Ó Cdk1 Ó Cyclin B1
Ó Cdc25B G2/M phase arrest [83]
Ó Cdc25C
AITC PC3 Ó Cdk1 ns
Ó Cdc25B G2/M phase arrest [83]
Ó Cdc25C
BITC DU 145 ns Ó Cyclin B1
Ó Cdc25C G2/M phase arrest [91]
ÒWEE1
PEITC-NAC LNCaP Ó Cdk1 Ó Cyclin B1 ns G2/M phase arrest [85]
PEITC LNCaP Ó Cdk1 Ó Cyclin B1 ns G2/M phase arrest [85]
PEITC PC3 Ó c-Myc ns Ó p21 mRNA and protein levels G0/G1 phase arrest [66]
PEITC DU 145 Ó Cdk1 ns
Ó Cdc25C
G2/M phase arrest [86]Ò p53
ÒWEE1
PEITC PC3 Ó Cdk1 ns Ó Cdc25C G2/M phase arrest [84]
PEITC LNCaP Ó Cdk1 Ó Cyclin B1 ns G2/M phase arrest [85]
SFN-NAC LNCaP ns Ó Cyclin D1 ns G1 phase arrest [95]
SFN LNCaP
Ó Cdk1 Ó Cyclin B1 Ó Cdc25C G2/M phase arrest [88]
ns ns Ò p21 G2/M phase arrest [88]
Ò p53
Ó Cdk4 ns ns S phase arrest [88]
Ó Cdk6 ns ns S phase arrest [88]
SFN BPH1,PC3 ns ns Ò p21 mRNA and protein levels G2/M phase arrest [96]
SFN PrEC ns ns « p21 mRNA protein levels « G2/M phase [96]
Abbreviations: Ò, enhanced expression or protein levels; «, no change in expression or protein levels;
Ó, reduced expression or protein levels; AITC, allyl isothiocyanate; BITC, benzyl isothiocyanate; BPH1, benign
hyperplasia epithelial cells; Cdc, cell division cycle proteins; Cdk, cyclin-dependent kinase; ns, not specified;
p21, cyclin-dependent kinase inhibitor 1; PEITC, phenethyl isothiocyanate; PEITC-NAC, N-acetylcysteine
conjugate of phenethyl isothiocyanate; PrEC, normal prostate epithelial cell line; SFN, sulforaphane; SFN-NAC,
N-acetylcysteine conjugate of sulforaphane.
4.2. Induction of Apoptosis
4.2.1. Intrinsic and Extrinsic Pathway
Type I programmed cell death (PCD) or apoptosis is carried out by activating both extrinsic and
intrinsic pathways [97]. It seems that certain ITCs could induce apoptosis in PCa cells by acting on
both pathways (Table 3).
Table 3. Effects of ITCs on apoptosis in vitro.
ITC Cells Factor Ref.
AITC PC3, LNCaP Ó Bcl-2 [83]
AITC LNCaP Ó Bcl-XL [83]
BITC PC3 Ó Bcl-2 [98]
PEITC PC3 Ó Bcl-2, Ó Bcl-XL(+) caspase-8, caspase-9 pathways [84]
PEITC DU 145 (+) caspase-8-, caspase-9-, caspase-3 -dependent pathways [86]
PEITC LNCaP, PC3 (+) Bcl-2, (-) complex III activity [92]
PEITC PC3 Ó XIAP, Ó survivin [92]
PITC DU 145 Ó Bcl-2, Ò Bax(+) caspase 3 [86]
SFN PC3 Ò Bax, Ó Bcl-2, modified Bax:Bcl-2 ratio [99]
SFN DU 145 Ó Bcl-2 [99]
SFN LNCaP, PC3 (+) Bax [100]
SFN PC3 Ò Apaf-1, (+) transcriptional E2F1 [100]
SFN PC3 Ó Survivin [101]
SFN DU 145 (+) Caspase [64]
Molecules 2016, 21, 626 8 of 28
Table 3. Cont.
ITC Cells Factor Ref.
SFN PC3 (+) Caspase [99]
SFN PC3 Ò Bid, Ò Smac/Diablo, Ò ICAD, Ò cytochrome c, Ò c-IAP1, Ò HSP27,
Ò Lamin A/C; Ò BRE [94]
SFN PrEC, LNCaP, PC3 Ò Bax, ÒMEK4, Ó Lamin3 [94]
SFN LNCaP Ó Bim, Ó Bmf [94]
SFN PrEC, PC3 Ó ASK1 [94]
SFN PrEC Ó cytochrome c, Ó c-IAP1, Ó HSP27 [94]
SFN PC3, BPH1 (+) Multicaspase [96]
SFN BPH1 Ó HDAC2 [96]
SFN BPH1, LNCaP, PC3 (´) HDAC, Ó HDAC3, Ó HDAC6 [96]
SFN PC3 Ó Survivin [101]
SFN BPH1, LNCaP Ó HDAC4 [96]
SFN PC3 Ó Bid, Ó Smac/Diablo, Ó ICAD [94]
Abbreviations: Ò, enhanced expression or protein levels; Ó, reduced expression or protein levels; (+), activation;
(´), inhibition; AITC, allyl isothiocyanate; Apaf-1, apoptosis protease-activating factor-1; ASK 1, apoptosis
signal-regulating kinase 1; Bax, Bcl-2-like protein 4; Bcl-2, B-cell lymphoma 2; Bid, BH3 interacting-domain
death agonist; Bim, pro-apoptotic BH3-only protein; Bcl-XL, B-cell lymphoma-extra large; BITC, benzyl
isothiocyanate; Bmf, Bcl-2-modifying factor; BPH1, benign hyperplasia epithelial cells; BRE, brain and
rproductive organ-epressed protein; HDAC, histone deacetylases; HSP27, heat shock protein 27; IAP, inhibitor
of apoptosis proteins; ICAD, inhibitor of caspase activated DNase; MEK4, mitogen-activated protein kinase 4;
PEITC, phenethyl isothiocyanate; PITC, structural analogue of PEITC; PrEC, normal prostate epithelial cell line;
SFN, sulforaphane; Smac/Diablo, second mitochondria-derived activator of caspases/Diablo homolog; XIAP,
X-linked inhibitor of apoptosis protein.
The intrinsic pathway is triggered by different stimuli such as stress, resulting in the activation
of Bax [B-cell lymphoma-2-like protein 4 (Bcl-2-like protein 4)] (via the activation of Bcl-2 BH3-only
protein), the production of reactive oxygen species (ROS) and the ceramide that serve as second
messengers acting on the mitochondria. This causes the release of mitochondrial apoptogenic factors
cytochrome c, endonuclease G (Endo G) and apoptosis iducing fctor (AIF). Cytochrome c is combined
with pro-caspase 9, dATP and APAF-1 to form the apoptosome that triggers the apoptosis through the
activation of caspase 9 which then activates the executioner caspase 3 [97].
PEITC is involved in ROS production [86,102] derived from the inhibition of oxidative
phosphorylation (OXPHOS), thus causing the activation of proapoptotic protein Bax (LNCaP and PC3
cells) [102] and the inhibition of complex III activity. The latter could be due to the fact that being
a hydrophilic molecule could modify covalently sulfhydryl groups of complex III of the mitochondrial
respiratory chain [103]. In addition, PEITC increases the mitochondrial release of cytochrome c and
Endo G [86]. Similarly, SFN-induced apoptosis is initiated with the genesis of ROS and regulated
by Bax and Bak [90,104]. ROS production is followed by the disruption of mitochondrial membrane
potential and cytosolic release of cytochrome c in PC3 cells [104].
The extrinsic pathway is mediated by the activation of cell-death receptors (TNFR superfamily)
that involves the recruitment and activation of caspases 8 and 10 (initiator caspases), which, in turn,
induces the activation of caspase 3 (effector caspase) through the formation and activation of the
death inducing signaling complex (DISC). The cleavage of death substrates by caspase 3 is the main
executor of apoptosis hallmark (DNA fragmentation, nuclear fragmentation, membrane blebbing and
other biochemical and morphological changes) [97]. Suppression of caspase 3 expression in PCa cells
markedly decreases their sensitivity to apoptosis, thus contributing to cancer progression [105].
It has been shown that PETIC would act not only via the mitochondria in order to reduce
mitochondrial membrane potential (∆Ψm) and to increase Ca2+, but also through the extrinsic pathway
by increasing the activity of caspases 3, 8 and 9 in DU 145 cells [86]. However, this ITC actives caspase-8
and -9 pathways (10 µM) in PC3 cells [84].
Treatment with BITC (DU 145 cells) promotes apoptosis via the mitochondrial signaling pathway
triggered by ROS production (12 h post-treatment) followed by Ca2+ increase, ∆Ψm decrease and AIF
and Endo G release. Additionally, BITC increases caspase 3, 8 and 9 activity [91].
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There is growing evidence that the extrapolation of the anti-apoptotic mechanism of action
between ITCs is not admissible [92]. PEITC, but not PITC, induces apoptosis by both caspase-8- and
-9-mediated pathway, which is decreased by specific inhibitors of caspase-8 and caspase-9 and general
caspase inhibitor. It is considered that the expression of Bcl-2 fails to confer resistance to apoptosis
induced by PEITC [84]. However, SFN activates caspases to trigger apoptosis both in DU 145 [64] and
PC3 human androgen-independent cells [99].
4.2.2. Anti-Apoptotic/pro-Apoptotic Proteins
It is well known that the Bcl-2 protein family is an important gatekeeper of the apoptotic response.
This family includes anti-apoptotic proteins (such as Bcl-2, Bcl-XL or BLL-B) or pro-apoptotic proteins
(Bax, Bak, etc.) interacting among them. The former interact with and inhibit pro-apoptotic proteins;
the latter cause the release of cytochrome c from the mitochondria by inducing the activation of
caspases to execute cell death program [97].
Blc-2 protein expression varies depending on the progression stages of PCa cells [106]. Bcl-2 is
not expressed in normal epithelial cells but its overexpression in LNCaP cells protects them from
apoptosis and confers resistance to androgen ablation treatment [107]. Moreover, the upregulation
of Blc-2 is required for the progression of LNCaP cells from the androgen-dependent to the
androgen-independent state [108] and predicts recurrence and poor survival of localized cancer
after radical prostatectomy [109,110]. AITC treatment (20 µM) of PC3 and LNCaP cells results in
a significant reduction in the levels of Bcl-2 in both cell lines but only reduces the expression of Bcl-XL
in the LNCaP cells [83]. To equal treatment regimen (10 µM), PEITC and PITC induce apoptosis or
not in PC3 cells, respectively. The apoptosis induced by PEITC is attributed to the reduction that it
produces in Bcl-2 (more than 50% at 24 h) and Bcl-XL (more than 40% at 24 h). However, the sensitivity
of these cells to PEITC-induced apoptosis is not influenced by the overexpression of Bcl-2 [84]. These
findings, if taken together, support the hypothesis that the effect of ITCs is structure-dependent. BITC
treated PC3 cells show a decreased expression of Bcl-2 from 6 to 48 h post-treatment [98]. The Bcl-2/Bax
ratio (intracellular suppressor of apoptosis/apoptotic agonist) in cells determines the existence or
absence of apoptosis [111]. PITC induces the expression of Bax, but inhibits the expression of Bcl-2
(DU 145 cells), thus contributing, at least in part, to the activation of caspase 3 and to the activation
of the intrinsic apoptosis pathway [86]. SFN upregulates Bax [99] in PC3 cells and downregulates
the expression of Bcl-2 in DU 145 cells [64,99]. SFN causes Bax activation in LNCaP (10 µM, 20 µM,
40 µM) and PC3 (40 µM), showing LNCaP more sensitivity to SNF-induced apoptosis. The differential
sensitivity towards SFN-induced apoptosis could be attributed to the difference in Bax activation
profile or androgen responsiveness among these cell lines. P53 knockdown in LNCaP cells does not
confer protection against SFN-induced apoptosis. Therefore, it seems that the difference in p53 status
among these cells does not contribute to the difference in sensitivity to death [100].
4.2.3. Inhibitor of Apoptosis Proteins (IAPs)
Regardless of the members of the family Bcl-2, other proteins can antagonize apoptosis, including
IAPs, FLIPs and Faim3 [97]. IAPs include neuronal apoptosis inhibitory protein (NAIP), IAP-like
protein 2 (ILP2), cellular IAP 1 (cIAP1), cIAP2, baculoviral IAP repeat containing ubiquitin-conjugating
enzyme (BRUCE), X-linked inhibitor of apoptosis protein (XIAP), survivin and livin (ML-IAP), among
others [112]. IAPs play an essential role in the inhibition of apoptosis since they cause: direct inhibition
of caspases (XIAP) [97,112], kidnapping of pro-apoptotic molecules such as SMAC/DIABLO (cIAP1/2,
survivin, livin), activation of the pro-survival NF-κB pathway (cIAP1/2, XIAP), ubiquitin-mediated
degradation and non-degradative inactivation of caspases (cIAP1/2, XIAP), etc. [112].
The evasion of apoptosis in the PCa occurs both by an alteration in function and the levels of
apoptosis regulators. XIAP and survivin are overexpressed in human PCa [113,114]. This fact is
associated with PCa recurrence [114]. Also, the expression of cIAP12 correlates positively with the
pathological T stage and the positive surgical margins. Likewise, there is correlation between survivin
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expression and perineural invasion [105]. PEITC exposure causes apoptosis associated to XIAP and
survivin protein downregulation, regardless of the p53 status or the sensitivity to androgens (observed
both in PC3 and LNCaP cells), being more sensitive to PEITC-induced apoptosis LNCaP cells in
comparison to PC3 ones (2.5–5 µM). Conversely, overexpression of survivin protects these cells from
the pro-apoptotic effect of PEITC [92] and SFN [101].
4.3. Inhibition of Migration and Metastasis
Epithelial mesenchymal transition (EMT) is a key process in carcinogenesis and the metastatic
PCa [115], involving loss cell polarity and cell-cell adhesion, acquisition of cell mobility,
downregulation of E-cadherin, upregulation of vimentin, etc. (Figure 3a). As a consequence, PCa cells
can invade (Figure 3b), migrate and metastasize (Figure 3c) [116,117].
The invasiveness of organ-confined Pcas is modulated by androgens, acting on programs of
gene expression by transcription factor-encoding genes of the ETS family (ERG, ETV1, etc.) [118].
When organ-confined tumor cells overexpress ERG and present transcriptional upregulation of their
downstream target chemokine receptor type 4 gene (CXCR4), increased cell motility is observed [119].
Both CXCR4 expression [120,121] and cell motility are modulated by androgens [121]. In particular,
LNCaP cell motility is modulated by androgens in a dose-dependent manner [121]. PEITC, BITC and
SFN suppress CXCR4 expression and cell migration in LNCaP, 22Rv1 (human prostate carcinoma
epithelial cell line), C4-2 (same phenotype as LNCaP), and PC3 (Figure 3c) [122].
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mechanism in PCa cells in vitro. (a) During EMT epithelial cells decrease adhesion, change their
morpholo y, p larity and p siti n. EMT is characterized by a dowregul tio (Ó bold arrow) and
upregulati n (Ò bold arrow) of g nes that are characteristic of an epithelial nd mesenchymal phenotype,
respectively; The invasive (b) and migration (c) capacities re increased in the cells overexpressing
CXCR4, MMP-2, MMP-9, MMP-3 (Ò bold arrow). Inhibitory effects of ITCs are represented by
blue arrows (Ò, enhanced expression, activity or protein levels; Ó, reduced expression, activity or
protein levels). Abbreviations: BITC, benzyl isothiocyanate; BM, basement membrane; CXCR4,
chemokine receptor type 4; ECM, extracellular matrix; EMT, epithelial- mesenchymal transition; MMP-2,
matrix metalloproteinases (gelatinase-A); MMP-9, matrix metalloproteinases (gelatinase-B); PEITC,
phenethyl isothiocyanate; SFN, sulforaphane; SFN-NAC, N-acetylcysteine conjugate of sulforaphane;
TJs, tight junctions.
It seems that SFN reduces the levels of proteins required for EMT as well as differentiation,
self-renewal, tumorigenesis, migration and metastasis in DU 145 and PC3 cells [123]. In particular,
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SFN (15 µM) inhibits migration and invasion by changing the morphology of DU 145 cells and by
activating ERK1/2 and downstream signaling. These events lead to upregulation of E-cadherin and
downregulation of CD44v6, which reduce MMP-2 expression and activity [124].
Likewise, it is thought that the SFN may act on the expression of MMP-3 mediated by Notch
signalling. This is a complex involving interplay among receptors (Notch1, Notch2, Notch3, and
Notch4) and ligands (Jagged1, Jagged2, Delta-like and ligands [Dll1, Dll3, and Dll4]), which play
a crucial role in PCa development and metastasis [125,126]. Notch overexpression has been associated
to PCa metastasis and EMT [127]. Conversely, the knockdown of Notch1 inhibits the invasion of
PCa cells associated to the inhibition of MMP-9 [127]. SFN (10 or 20 µM) inhibits cell migration and
activates Notch signaling, which is characterized by Notch1, Notch2, and Notch4 cleavage (active form)
and increased transcriptional activity in PC3, LNCaP and LNCaP-C4-2B, regardless of the androgenic
response or p53 status. Nevertheless, knockdown of Notch1, Notch2 or Notch4 has not a relevant
effect on SFN-mediated inhibition of cell migration [128]. In line with these data, the transition from
LNCaP to LNCaP´C4-2 cells (androgen-independence) does not affect PEITC-mediated changes in
Notch signaling components in a relevant way [129]. The knockdown of Notch2 confers protection
against PEITC-induced apoptosis in LNCaP or PC3 cells. Also, the knockdown of Notch2 increases
PEITC-mediated inhibition of LNCaP and PC3 cell migration, attributed to downregulation in the
expression of MMP-9 and urokinase plasminogen activator [129].
4.4. ADT Resistance
Although androgen deprivation constitutes the standard therapy in PCa, tumor cells may develop
resistance to it. Certain ITCs may have some inhibitory effects on some of the main mechanisms
responsible for this resistance, as shown below.
It is postulated that, because of their capacity for self-renewal and differentiation and
apoptosis-resistance, CSCs in PCa could be responsible not only for the cancer formation, but also
for the progression and metastasis. What is more, they could be resistant to chemotherapy and be
responsible for the recurrence after treatment [123,130,131] and resistance to ADT [132]. The SFN seems
to decrease the ability of self-renewal and spheroidal growth around 50% and 80%, respectively [123].
In a normal prostate gland, androgen-dependent AR signaling has a counterbalanced effect on
epithelial cells growth; acting on the stromal cells stimulates the release of andromedins inducing
andromedin-driven epithelial cell growth, whereas it causes G0 growth arrest within epithelial cells.
However, the suppressor role of growth in normal cells is transformed into oncogenic in PCa cells
mediated by c-Myc [133]. PEITC can reduce the growth of LNCaP cells mediated by the expression of
c-Myc [66].
Furthermore, androgen sensitivity of PCa cells could be, at least in part, conditioned by
SFN-induced changes on a broad spectrum of genes expression. Specificity protein 1 (Sp1) transcription
factors are overexpressed in PCa and are associated with poor prognosis [134]. PCa cells overexpress
in vitro, among others, three categories of genes under Sp1 upstream or downstream control, which
are involved in the regulation of apoptosis, cellular response to stress, and cell cycle [94]. Sp1 could
be a major transcriptional mediator of SFN-induced changes in these genes, depending on the cell
line [normal (PrEc), early (LNCaP) or on late-stage PCa (PC3)] and the time of exposition (6 h and
24 h). In LNCaP cells, a broad spectrum of genes upstream (p53, NFκB, c-Myc, E2F1, BRCA1, etc.) and
downstream (EGFR, p21, cyclin D1, cyclin E2, Cdk4, Cdc25A, E2F1 and p21) of Sp1 are altered. Only in
PC3 cells, SFN treatment causes a strong increase in the expression of pro-apoptotic (Bid, Smac/Diablo,
and ICAD), cell migration, extracellular matrix, and angiogenesis-related genes. In LNCaP cells, the
predominant effect is related to the cell cycle arrest [94].
Signal transducers and activators of transcription (STATs) together with androgens, RAS/MAPK,
PI3K/AKT and Notch signaling pathways contribute to modulate PCa CSCs chemoresistance and
self-renewal [135]. Specifically, STAT activity, with the induction of target genes, promotes proliferation
at the time that inhibits the apoptosis of tumor cells, increases angiogenesis and facilitates tumor
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immune evasion [136]. STAT3 integrates different signals involved in the metastatic castration-resistant
PCa (mCRPC), such as the reactivation of AR or EMT and also mediates the interaction of tumor
cells with the microenvironment and immune activation, thus allowing PCa cells to escape immune
detection and to promote an enabling environment for immune growth and tumor metastasis [137].
Constitutive STAT3 is required for the survival of prostatic tumor cells and its inhibition reduces cell
growth and promotes apoptosis [138]. Direct or indirect targeting the STAT3 signaling pathway has
been explored in order to counteract cancer [139]. It is thought that hyperactive STAT3 is oncogenic
in PCa [140] and has been observed in around 50% of PCa [141]. Moreover, high STAT3 activation is
associated with increased PCa malignancy with high Gleason score [141].
STAT3 activation in PCa cells is mediated by the activation of different upstream Janus kinase
(JAK) depending on the cell line, being JAK2 and JAK1 for DU 145 and NPR-145 cells, respectively.
However, the direct inhibition of STAT3 induces apoptosis in both cell lines [138]. IL-6 can act as
a growth factor autocrine and paracrine in CaP cells that activates JAK/STAT3 and mitogen-activated
protein kinase (MAPK) pathways. Androgen-resistant cells (DU 145 and PC3) constitutively express
IL-6 [141]. On the other hand, activated STAT3 phosphorylation and the JAK/STAT3 pathway ensure
the AR signal maintenance and increase IL-6-induced AR activation [142]. STAT3 activation by IL-6
may be abolished by CK2 inhibition [143].
PEITC reduces constitutive and IL-6-induced JAK2/STAT3 phosphorylation in DU 145 cells [87].
It seems that PEITC, but not PITC, suppresses the proliferative activity by the inhibition of JAK/STAT3
activation in DU 145 cells [93]. However the mechanism has not been fully elucidated. A synthetic
analogue of broccoli-derived L-isomer of SFN (D, L-SFN) not only decreases the constitutive (DU
145 cells) and IL-6-induced STAT3 phosphorylation (DU 145 and LNCaP cells) but also its upstream
regulator JAK 2. While the effect on the IL-6-induced STAT3 phosphorylation can be seen both in
DU 145 as LNCaP cells, the effect on constitutive phosphorylation only occurs in DU 145 cells [144].
On the other hand, the phosphoinositide 3-kinase (PI3K)-AKT-mammalian target of rapamycin or
the mechanistic target of rapamycin (mTOR) signaling pathway is involved in the ADT [145]. SFN
treatment decreases mTOR signalling in PC3 cells [101] and likewise, BITC inhibits mTOR activity in
androgen-independent PCa cells in a dose-dependent manner [98].
5. In Vivo Studies
Although cellular studies constitute an important step in the development of drugs, demonstrating
preventative [146–148] and/or therapeutic [146,147] efficacy in suitable animal models and validating
cellular observations in vivo are a condition sine qua non for clinical trials investigating potential
anticancer agents. Inconsistencies in results between in vitro and in vivo systems concerning the effect
of ITCs have been observed (Table 4) and although the reasons for these discrepancies are unclear, the
following explanations have been suggested:
(i) the dose of ITCs: the necessary concentration of ITC might not have been administered in vivo,
thus being required a more intensive dosing regimen to elicit a response;
(ii) the metabolism of ITCs: the exposure of cultured tumor cells to ITCs can lead to a very high
intracellular accumulation of them, which may not be possible in vivo due to the rapid excretion
of the conjugates of ITCs;
(iii) the activation of in vivo (but not in vitro) mechanisms to counteract the anticancer effect of the
compounds (p.e. induction of prosurvival pathways, increased expression of IAPs, etc.).
These observations raise caution with regard to the extrapolation of results between in vitro and
in vivo assays.
The selection of appropriate biological models, with optimal sensitivity and specificity, is
an important aspect in any research setting. Although an ideal animal model for PCa does not exist, the
transgenic adenocarcinoma of the mouse prostate (TRAMP) model closely mirrors the pathogenesis of
human PCa. One of the major strengths of this model is that the cancer arises from normal prostate
Molecules 2016, 21, 626 13 of 28
epithelial cells in their natural tissue microenvironment and furthermore, it has a well-defined course
of disease progression with resemblance to human PCa development, this is metastasis to distant sites,
progression to androgen independence, and neuroendocrine differentiation [12].
Table 4. Discrepancies in the results between ITC studies in cultured prostate cancer cell lines and
animal models.
ITC Factor In Vitro In Vivo
PEITC Bak Ò [149] Ó [150]
PEITC Bcl-XL Ó [84,149] Ò [150]
PEITC Vimentin Ò [151] Ó [151]
SFN Bcl-XL « [99] Ó [147]
SFN Bid « [99] Ò [152]
Abbreviations: Ò, enhanced expression;«, no change in expression; Ó, reduced expression; Bak, Bcl-2 homologous
antagonist/killer; Bcl-XL, B-cell lymphoma-extra large; Bid, BH3 interacting-domain death agonist; PEITC,
phenethyl isothiocyanate; SFN, sulforaphane.
Knowing the pharmacokinetics of ITCs is critical. In relation to this aspect, ITCs-mediated
anticancer effects in animal models occur at micromolar concentrations, which are achievable in
humans through a dietary intake of cruciferous vegetables. For instance, it has been estimated that
consumption of one ounce of watercress could yield up to 60 µmol of PEITC [153]. Furthermore,
dietary ITCs administration appears to be safe and well tolerated. Xiao et al. [150] have shown that
the PEITC-supplemented diet (12 µmol PEITC/day) does not result in any toxic effects as evidenced
by no change in the body weight or the presence of signs such as impaired movement and posture,
indigestion or diarrhea and areas of redness or swelling.
There are more than one hundred naturally occurring ITCs, and of these, PEITC and SFN, alone
or in combination with other compounds (docetaxel [154], curcumin [146,155], tumor necrosis factor
(TNF)-related apoptosis ligand (TRAIL) [123,147]), have received the most attention. When combined
with other chemopreventive agents, ITCs can improve the efficacy of conventional therapies and reduce
their effective dose, thereby ameliorating untoward side effects. For example, Shankar et al. [147] have
observed that the combination of SFN and TRAIL is more effective in inhibiting tumor growth, invasion,
metastasis and angiogenesis and inducing apoptosis than TRAIL alone. In relation to the apoptotic
effect, it has been observed that the treatment of mice with TRAIL results in an enhanced expression of
proapoptotic proteins (Bax, Bak), higher caspase-3 and caspase-8 activities, and an inhibited expression
of antiapoptotic proteins (Bcl-2 and Bcl-XL); these effects are higher when SFN is coadministered
with TRAIL.
The mechanisms behind the anticancer effects of ITCs are not fully understood, but known
responses to these natural products in in vivo assays include: (i) prevention of cancer development in
animal models [12,65,99,146–152,154–161]; (ii) suppression of cancer cell viability in association with
apoptosis induction [12,148,152,155] and Atg5-dependent autophagic cell death [12,157]; (iii) inhibition
of metastasis [12,147,151,152]; (iv) inhibition of angiogenesis [12,147,148].
5.1. Prevention of Cancer Development in Animal Models
ITCs have proved to be effective chemoprotective agents in PCa in subcutaneous and orthotopic
xenograft models of cancer in nude mice and in ovo CAM-assays, as well as transgenic animal cancer
models, and their effect has been demonstrated both by oral administration [12,65,99,147–152,154–161]
and i.p. injection [146,162]. Oral gavage of 5.6 µmol SFN is highly effective in suppressing the
growth of PC3 xenografts in male nude mice thrice weekly; 10 and 20 days after starting therapy,
the average tumor volumen in SFN-treated mice is >50% and ~71%, respectively, lower than that
of control mice [99]. Additional studies using TRAMP mice showed that a similar dosing regimen
(6 µmol SFN, three times/week) inhibits PCa progression, this is, it prevents the incidence (23%–28%)
and/or burden (24%–44%) of prostatic intraepithelial neoplasia and well-differentiated carcinoma in
the dorsolateral prostate of SFN-treated mice compared with that of control mice [152].
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5.2. Suppression of Cancer Cell Viability in Association with Apoptosis and/or Autophagy Induction
ITCs-mediated inhibition of prostate carcinogenesis is associated with a reduced cellular
proliferation [12,65,123,147,152,155,160–162] and the induction of apoptotic [12,65,92,99,146,148,150,
152,154–156,159] and autophagic [12,157] cell death.
5.2.1. Cellular Proliferation
ITC administration decreases the proliferation of AIPC cells, although it is ineffective in
androgen-dependent ones [148] (Table 5). Oral gavage of SFN causes a statistically significant decrease
in cell proliferation in the DLP of TRAMP mice, as evidenced by the reduced expression of the
molecular proliferation marker PCNA (~40 % lower in mice treated with SFN compared with control
mice) [152], which serves as a requisite protein for DNA polymerase δ-driven DNA synthesis and is
cell cycle regulated [163]. Likewise, other proliferation markers, such as Ki-67, are affected by ITC
treatment [12,123,147,161].
Table 5. ITCs inhibit the in vivo and ex vivo growth of prostate tumors by inhibiting tumor
cell proliferation.
ITC Factor Model (Cell Line) Ref.
BITC Ó Ki-67 TRAMP [161]
BITC Ó Cyclin D1 TRAMP [161]
BITC Ó Cyclin A TRAMP [161]
BITC Ó Cdk2 TRAMP [161]
PEITC Ó Akt TRAMP [155]
PEITC Ó FKHR TRAMP [155]
PEITC Ò IGFBP3 Subcutaneous xenograft (LNCaP) [160]
PEITC « Ki-67 Subcutaneous xenograft (LNCaP) [148]
PEITC Ó Ki-67 TRAMP [12]
PEITC « PCNA Subcutaneous xenograft (LNCaP) [148]
PEITC Ó PCNA TRAMP [155]
PEITC Ó PCNA Subcutaneous xenograft (PC3) [154]
PEITC Ó PDK1 TRAMP [155]
PEITC-NAC Ó Cyclin D1 Subcutaneous xenograft (PC3) [65]
PEITC-NAC Ó Cyclin E Subcutaneous xenograft (PC3) [65]
PEITC-NAC Ò p21 Subcutaneous xenograft (PC3) [65]
PEITC-NAC Ò p27 Subcutaneous xenograft (PC3) [65]
PEITC-NAC Ó pRb Subcutaneous xenograft (PC3) [65]
SFN Ó COX-2 Orthotopic assay (PC3) [147]
SFN Ó Cyclin D1 Orthotopic assay (PC3) [147]
SFN Ó IL-6 Orthotopic assay (PC3) [147]
SFN Ó IL-8 Orthotopic assay (PC3) [147]
SFN Ó Ki-67 Orthotopic assay (PC3) [147]
SFN Ó Ki-67 CAM xenograft (PC3) [123]
SFN Ó PCNA TRAMP [152]
SFN Ó PCNA Orthotopic assay (PC3) [147]
Abbreviations: Ò, enhanced expression; «, no change in expression; Ó, reduced expression; BITC, benzyl
isothiocyanate; CAM, chorioallantoic membrane; COX-2, cyclooxygenase-2; FKHR, forkhead transcription
factor FOXO1; IGFBP3, insulin-like growth factor binding protein 3; IL, interleukin; p21, cyclin-dependent
kinase inhibitor 1; p27, cyclin-dependent kinase inhibitor 1B; PCNA, proliferating cell nuclear antigen; PDK1,
pyruvate dhydrogenase kinase, iozyme 1; PEITC, phenethyl isothiocyanate; PEITC-NAC, N-acetylcysteine
conjugate of phenethyl isothiocyanate; SFN, sulforaphane; pRb, Rb protein; TRAMP, transgenic adenocarcinoma
of the mouse prostate model.
ITCs impede the progression of PCa at least by downregulating the Akt signaling pathway, which
is involved in amplifying cell-survival signals by inactivating its downstream targets, such as members
of the forkhead family [164]. Barve et al. [155] have shown reduced expression levels of PDK1, Akt
and FKHR proteins in the prostatic tissues of TRAMP mice that were fed a diet supplemented with
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PEITC compared with mice that received control diet. Furthermore, the induction of insulin-like
growth factor binding proteins (IGFBP) through regulation of inflammatory pathways could result in
lowered tumor growth. In this respect, ITCs may decrease inflammation through modulation of IL-6
mediated pathways [147] that involves control of IGFBP3, thus resulting in the regulation of tumor cell
proliferation [160].
On the other hand, growth inhibition of tumors is also associated with a reduction in cells
undergoing mitosis due to the accumulation of the inactive Cdk1/cyclin B kinase complex. Thus,
Srivastava et al. [162] have observed accumulation of cells in G2/M phase in the tumors of AITC-treated
mice when compared with control tumors because of the lack of activation of Cdk1 mediated by Cdc25B
and Cdc25C. However, it is also possible that cell cycle arrest occurs at another moment of it, such as
G1 to S phase transition [65,147].
5.2.2. Apoptosis
Apoptosis induction is regarded as an important mechanism for ITC-mediated inhibition of
the development of AIPC [65,99]; however, like it was commented previously in relation to cellular
proliferation, these natural compounds lack effects on androgen-mediated pathways [148]. Thus, the
percentage of apoptotic cells is significantly higher (~3.3-fold) in PC3 tumor sections from SFN-treated
mice than in controls [99]; and likewise, the presence of DNA strand breaks and abundant necrotic
regions in tumors from PEITC-NAC fed mice are indicative of this mode of PCD [65]. Although
molecular regulators of this proapoptotic response are not fully known, several biomarkers have been
suggested in order to assess the proapoptotic effect of ITCs in future studies [12,92,154,159]. In this
respect, it is important to underline the role of Bcl-2 and IAP family proteins, among others (Table 6).
Table 6. ITCs inhibit the in vivo and ex vivo growth of prostate tumors by inducing apoptosis.
ITC Factor Model (Cell Line) Ref.
AITC « Bax Subcutaneous xenograft (PC3) [162]
AITC Ó Bcl-2 Subcutaneous xenograft (PC3) [162]
AITC « Bcl-XL Subcutaneous xenograft (PC3) [162]
AITC Ò Bid Subcutaneous xenograft (PC3) [162]
AITC « Clusterin TRAMP [12]
PEITC Ò Bad TRAMP [155]
PEITC « Bad Subcutaneous xenograft (PC3) [146]
PEITC Ó Bak Subcutaneous xenograft (PC3) [150]
PEITC « Bak Subcutaneous xenograft (PC3) [154]
PEITC Ò Bax Subcutaneous xenograft (PC3) [150]
PEITC « Bax Subcutaneous xenograft (LNCaP) [148]
PEITC « Bax Subcutaneous xenograft (PC3) [154]
PEITC Ó Bcl-2 Subcutaneous xenograft (PC3) [154]
PEITC Ò Bcl-XL Subcutaneous xenograft (PC3) [150]
PEITC Ò Bid Subcutaneous xenograft (PC3) [150]
PEITC Ó Bok Subcutaneous xenograft (PC3) [150]
PEITC « Caspasa 3 Subcutaneous xenograft (LNCaP) [148]
PEITC Ò Caspase-3 TRAMP [155]
PEITC Ò Caspase-3 Subcutaneous xenograft (PC3) [146]
PEITC Ó Clusterin TRAMP [12]
PEITC Ó GSK3βα Subcutaneous xenograft (PC3) [146]
PEITC Ó IκBα Subcutaneous xenograft (PC3) [146]
PEITC Ó IKKβα Subcutaneous xenograft (PC3) [146]
PEITC « p66Shc Subcutaneous xenograft (PC3) [159]
PEITC Ò PARP Subcutaneous xenograft (PC3) [146]
PEITC Ó Pin1 Subcutaneous xenograft (PC3) [159]
PEITC Ò RANBP1 Subcutaneous xenograft (LNCaP) [160]
PEITC Ó Survivin TRAMP [92]
PEITC Ó XIAP TRAMP [92]
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Table 6. Cont.
ITC Factor Model (Cell Line) Ref.
PEITC « XIAP Subcutaneous xenograft (PC3) [154]
PEITC-NAC Ò PARP Subcutaneous xenograft (PC3) [65]
SFN Ò Bad TRAMP [152]
SFN Ò Bak Orthotopic assay (PC3) [147]
SFN Ò Bak TRAMP [152]
SFN Ò Bax Orthotopic assay (PC3) [147]
SFN Ò Bax Subcutaneous xenograft (PC3) [99,156]
SFN Ò Bax TRAMP [152]
SFN Ó Bcl-2 Orthotopic assay (PC3) [147]
SFN Ó Bcl-2 Subcutaneous xenograft (PC3) [99]
SFN « Bcl-XL Subcutaneous xenograft (PC3) [99]
SFN Ó Bcl-XL Orthotopic assay (PC3) [147]
SFN Ò Bid Subcutaneous xenograft (PC3) [99]
SFN Ò Bid TRAMP [152]
SFN Ò Caspase 3 CAM xenograft (PC3) [123]
SFN Ò Caspase-3 Orthotopic assay (PC3) [147]
SFN Ò Caspase-8 Orthotopic assay (PC3) [147]
SFN Ó Clusterin TRAMP [12]
SFN ÓMcl-1 TRAMP [152]
SFN Ò PARP TRAMP [152]
Abbreviations: Ò, enhanced expression; «, no change in expression; Ó, reduced expression; AITC, allyl
isothiocyanate; Bad, Bcl-2-associated death promoter; Bak, Bcl-2 homologous antagonist/killer; Bax, Bcl-2-like
protein 4; Bcl-2, B-cell lymphoma 2; Bcl-XL, B-cell lymphoma-extra large; Bid, BH3 interacting-domain death
agonist; Bok, Bcl-2 related ovarian killer; CAM, chorioallantoic membrane; GSK3, gycogen synthase kinase 3;
IκBα, nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha; IKKβα, IκB kinase
beta alpha; Mcl-1, myeloid cell leukemia 1; p66Shc, 66-kDa Src collagen homologue (Shc) adaptor protein; PARP,
poly(ADP-ribose) polymerase; PEITC, phenethyl isothiocyanate; PEITC-NAC, N-acetylcysteine conjugate of
phenethyl isothiocyanate; Pin1, prolyl isomerase; RANBP1, ras-related nuclear protein (RAN) binding protein 1;
SFN, sulforaphane; TRAMP, transgenic adenocarcinoma of the mouse prostate model; XIAP, X-linked inhibitor
of apoptosis.
The apoptotic response to ITCs in PCa cells is accompanied by a change in the ratio of
proapoptotic–anti-apoptotic Bcl-2 family members. The levels of proapoptotic proteins Bad, Bak,
Bax, and Bid are significantly upregulated in tumors of PEITC- or SFN-treated mice [99,150,152,156].
Additionally, the administration of these ITCs results in a marked decrease in the level of the
antiapoptotic proteins Bcl-2 and Mcl-1 [152,154]. Besides Bcl-2 family proteins, the proapoptotic
response to ITCs in PCa cells is associated with an altered expression of IAP family proteins, including
XIAP and survivin [12,92,154]. It is known that IAP overexpression in tumors correlates with
poor prognosis, aggressive disease and treatment resistance, and it is a strong predictor of human
PCa recurrence because IAP proteins play a critical role in the regulation of PCD by inhibiting
caspases [165]. Sakao et al. [92] have shown that oral gavage of PEITC is effective in suppressing XIAP
expression, which is accompanied by the activation of caspase 3 [146], and cleavage and inactivation
of PARP [65,146]. Recent evidences highlight the role of PARP in relation to androgen resistance and
progression of PCa [166].
5.2.3. Autophagy
Basal autophagy plays a critical role in maintaining cellular homeostasis and genome stability by
removing exhausted, redundant or unwanted cellular components. In relation to cancer, this catabolic
process acts by suppressing cell growth during the early stages of tumorigenesis [167] and it can be
modulated by ITCs. Thus, for example, oral administration of PEITC at low micromolar concentrations
arrests xenograft growth [157] and inhibits the progression of cancer by decreasing the expression of
p62 (its overexpression correlates with an aggressive phenotype in prostate tumors) as well as the
incidence and the size of poorly differentiated tumors [12]. Taking into account that the majority of
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PCa mortality is associated with an advanced disease, this fact is very important. The autophagic
effect associated to PEITC is characterized by the accumulation of autophagosomes and increased
expression of the microtubule-associated protein 1A/1B-light chain 3 (LC3) (Table 7) [12,157], which
may serve as an endpoint to assess the biological activity of PEITC in future clinical studies.
Table 7. ITCs inhibit the in vivo growth of prostate tumors by inducing autophagic cell death.
ITC Factor Model (Cell Line) Ref.
PEITC Ò LC3 Subcutaneous xenograft (PC3) [157]
PEITC Ò LC3 TRAMP [12]
PEITC Ó p62 TRAMP [12]
Abbreviations: Ò, enhanced expression; Ó, reduced expression; LC3, microtubule-associated protein 1 light chain 3;
p62, sequestosome 1 or p62/SQSTM1; PEITC, phenethyl isothiocyanate; TRAMP, transgenic adenocarcinoma of
the mouse prostate model.
5.3. Inhibition of Metastasis
Metastasis is a major cause of death in PCa patients [168]. Oral gavage of ITCs to TRAMP
mice prevents pulmonary metastasis incidence and multiplicity [152], being the area occupied by
the metastasis generally smaller compared with the area in control mice [12]. The pathogenesis of
metastasis is complex and it is controlled by multiple molecules [169], which can be regulated by
ITCs. In this respect, the influence of PEITC and/or SFN can be directed towards preventing the
attachment of cancer cells to form tumors or they can act after the tumor is formed, as it is described
below (Table 8).
Table 8. ITCs inhibit the in vivo and ex vivo growth of prostate tumors by inhibiting invasion
and metastasis.
ITC Factor Model (Cell Line) Reference
PEITC Ò E-cadherin TRAMP [12]
PEITC Ò Fibronectin 1 Subcutaneous xenograft (LNCaP) [160]
PEITC Ó Integrin β6 Subcutaneous xenograft (LNCaP) [160]
PEITC Ò Notch2 Subcutaneous xenograft (PC3) [129]
PEITC Ò Notch2 TRAMP [129]
PEITC Ó Vimentin TRAMP [151]
PEITC Ó CSC markers * Subcutaneous xenograft (PC3) [122]
SFN Ó CSC markers * CAM xenograft (PC3) [123]
SFN « E-cadherin TRAMP [152]
SFN ÓMMP-2 Orthotopic assay (PC3) [147]
SFN ÓMMP-7 Orthotopic assay (PC3) [147]
SFN ÓMMP-9 Orthotopic assay (PC3) [147]
SFN ÓMMP-14 Orthotopic assay (PC3) [147]
SFN Ó NF-κB Orthotopic assay (PC3) [147]
SFN Ó TGF-β1 Orthotopic assay (PC3) [147]
SFN Ó uPAR Orthotopic assay (PC3) [147]
Abbreviations: Ò, enhanced expression; «, no change in expression; Ó, reduced expression; CAM,
chorioallantoic membrane; CSC: cancer stem cells; MMP, matrix metalloproteinase; NF-κB, nuclear factor
kappa-light-chain-enhancer of activated B cells; Notch 2, neurogenic locus notch homolog protein 2; PEITC,
phenethyl isothiocyanate; SFN, sulforaphane; TGF-β1, transforming growth factor-β1; TRAMP, transgenic
adenocarcinoma of the mouse prostate model; uPAR, urokinase-type plasminogen activator receptor. * CD133,
CXCR4, Nanog, C-Met, EpCAM, CD44, or ALDH1.
On the one hand, the inhibitory effect of ITCs against metastasis can be dependent on the changes
in E-cadherin expression, a suppressor of the invasion and growth of epithelial cancers because of its
role in inhibition of epithelial to mesenchymal transition [170]. Dietary PEITC administration causes
a statistically significant E-cadherin overexpression in the DLP of TRAMP mice [12], with a loss of
expression of mesenchymal markers, such as vimentin [151].
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On the other hand, the ITC-mediated inhibition of metastasis is associated with the blockage of the
activation of NF-κB and its gene products, such as metalloproteinases, implicated in the degradation
of the extracellular matrix and the promotion of tumor cell invasion and dissemination [170].
Shankar et al. [147] have observed that the treatment of tumor-bearing nude mice with SFN is effective
in inhibiting MMP-2, MMP-7, MMP-9, MMP-14, TGF-β1 and uPAR expression. In relation to
TGF-β1, it is important to highlight that it acts as a survival factor inhibiting chemotherapy-induced
apoptosis in hormone-refractory PCa cells [171], which are suggested to possess cancer stem cell (CSC)
characteristics [130]. CSC are believed to be a major cause of the resistance that cancer cells develop
to drugs that initially shrink tumours [172], so CSC markers are a potential target for novel therapies
against advanced PCa. Labsch et al. [123] have shown that the in ovo treatment of the PC3 xenograft
tumors almost completely abolishes the expression of CSC markers, including CD133, CXCR4, Nanog,
C-Met, EpCAM, CD44, ALDH1. Besides factors previously mentioned, other mediators regulated
by ITCs which have been described to play a role in human PCa progression are integrin β6 [160],
fibronectin 1 [160] and Notch 2 [129].
5.4. Inhibition of Angiogenesis
Angiogenesis plays a central role in the progression of hormone-refractory PCa. Microvessel
density, a histological measure of tumor angiogenesis, correlates with Gleason score and predicts
PCa progression [173]. Although available antiangiogenic therapy is showing hopeful results in
advanced cancer, it is dose-limited due to adverse side effects [174], so new alternatives are necessary.
In this context, it has been shown that ITCs can indirectly influence prostate tumor growth by
microenvironment modulation, and specifically through altered angiogenesis. Hudson et al. [148]
observed that treatment with PEITC inhibits the growth of LNCaP PCa cell xenografts in athymic nude
mice without affecting cellular proliferation or apoptosis. It is thought that this effect is mediated by
decreasing microvessel density, because this ITC inhibits the expression of the marker of angiogenesis
PECAM-1/CD31 [148]. Likewise, PEITC alters morphology of the vessels [12], being considered as
a sign of good prognosis [175]. The vessels appear to be more rounded and “regular” in shape in the
DLP of TRAMP mice fed PEITC as opposed to the meandering and irregular vessels predominant
in the DLP of control mice [12]. Besides PECAM-1/CD31, other mediators of angiogenesis whose
expression can be modulated by ITC are shown in Table 9.
Table 9. ITCs inhibit the in vivo growth of prostate tumors by inhibiting angiogenesis.
ITC Factor Model (Cell Line) Reference
PEITC « PECAM-1/CD31 TRAMP [12]
PEITC Ó PECAM-1/CD31 Subcutaneous xenograft (LNCaP) [148]
PEITC « VEGF Subcutaneous xenograft (LNCaP) [148]
SFN « PECAM-1/CD31 TRAMP [152]
SFN Ó Akt Orthotopic assay (PC3) [147]
SFN Ó ERK1/2 Orthotopic assay (PC3) [147]
SFN Ó FOXO3a Orthotopic assay (PC3) [147]
SFN Ó HIF-1 α Orthotopic assay (PC3) [147]
SFN Ó IL-6 Orthotopic assay (PC3) [147]
SFN Ó IL-8 Orthotopic assay (PC3) [147]
SFN Ó TGF-β1 Orthotopic assay (PC3) [147]
SFN Ó VEGF Orthotopic assay (PC3) [147]
Abbreviations: «, no change in expression; Ó, reduced expression; ERK1/2, extracellular signal-regulated kinase
1/2; FOXO3a, forkhead box O3; HIF-1α, hypoxia-inducible factor 1-alpha; IL, interleukin; PECAM-1/CD31,
tumor platelet/endothelial cell adhesion molecule; PEITC, phenethyl isothiocyanate; SFN, sulforaphane;
TGF-β1, transforming growth factor-β1; TRAMP, transgenic adenocarcinoma of the mouse prostate model;
VEGF, vascular endothelial growth factor.
Angiogenesis suppression is not specific for one type of ITC, although these natural compounds
may have different mechanisms of action. For example, SFN inhibits microvessel density by
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suppressing VEGF expression [147], whereas PEITC alters angiogenesis without affecting this growth
factor [148].
Different in vivo experimental models can lead to distinct results in terms of efficacy of a particular
ITC, without knowing, on occasions, the true motives of this incongruity. In this respect, it is known
that markers of angiogenesis are suppressed when tumor-bearing nude mice are treated with SFN [147],
although this ITC cannot inhibit angiogenesis in TRAMP mice [152].
6. Conclusions
PCa is a clinically heterogeneous disease (indolent, localized or invasive and metastatic) with
multiple mechanisms and signaling pathways involved in its genesis and evolution, which could
develop resistance to conventional treatment. As a result, new therapeutic approaches are required.
It has been suggested that ITCs could have effect on different CaP cell populations, including CSCs and
androgen-dependent and androgen-independent epithelial cells, both in vitro and in vivo. In this way,
ITCs seem to be responsible for activating cell cycle arrest, apoptosis and autophagy. Likewise, they
also seem to exhibit activity against metastasis and angiogenesis, acting on epigenetic mechanisms
and different signaling pathways. Therefore, they offer an encouraging perspective for the research of
new approaches in the chemoprevention and treatment of CaP. In spite of these findings, more studies
are required because the effect of ITCs seems to be conditioned, among other factors, by the chemical
structure of ITCS, the cell type and tumor stage.
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